CA2704024C - Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals - Google Patents

Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals Download PDF

Info

Publication number
CA2704024C
CA2704024C CA2704024A CA2704024A CA2704024C CA 2704024 C CA2704024 C CA 2704024C CA 2704024 A CA2704024 A CA 2704024A CA 2704024 A CA2704024 A CA 2704024A CA 2704024 C CA2704024 C CA 2704024C
Authority
CA
Canada
Prior art keywords
hair
antibody
antibodies
binding
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2704024A
Other languages
English (en)
French (fr)
Other versions
CA2704024A1 (en
Inventor
Stefan Hofmann
Hans-Juergen Hamann
Rainer Fischer
Stefan Schillberg
Simon Oliver Vogel
Helga Schinkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2704024A1 publication Critical patent/CA2704024A1/en
Application granted granted Critical
Publication of CA2704024C publication Critical patent/CA2704024C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2704024A 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals Expired - Fee Related CA2704024C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021396 2007-11-02
EP07021396.2 2007-11-02
PCT/EP2008/009110 WO2009056280A1 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Publications (2)

Publication Number Publication Date
CA2704024A1 CA2704024A1 (en) 2009-05-07
CA2704024C true CA2704024C (en) 2016-05-31

Family

ID=40157719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704024A Expired - Fee Related CA2704024C (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Country Status (9)

Country Link
US (1) US20110263826A1 (enExample)
EP (1) EP2207806B1 (enExample)
JP (1) JP5386499B2 (enExample)
KR (2) KR20100102103A (enExample)
CN (1) CN101910198B (enExample)
AU (1) AU2008317953B2 (enExample)
CA (1) CA2704024C (enExample)
NZ (1) NZ585004A (enExample)
WO (1) WO2009056280A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550863A1 (de) 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
JP2978245B2 (ja) * 1990-03-05 1999-11-15 マリンクロット ベタリナリイ，インコーポレイテッド 寄生虫防除組成物ならびにその製造法および使用法
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
JPH06227955A (ja) * 1992-12-08 1994-08-16 Kanebo Ltd 染毛剤又は化粧料及び前処理剤並びに染毛方法
EP0673638A3 (en) * 1994-03-24 1996-10-16 Kao Corp Cosmetic composition containing antibodies.
US7067499B2 (en) * 2002-05-06 2006-06-27 Hercules Incorporated Cationic polymer composition and its use in conditioning applications

Also Published As

Publication number Publication date
JP2011502178A (ja) 2011-01-20
NZ585004A (en) 2012-04-27
US20110263826A1 (en) 2011-10-27
CN101910198B (zh) 2014-10-29
AU2008317953A1 (en) 2009-05-07
CN101910198A (zh) 2010-12-08
JP5386499B2 (ja) 2014-01-15
EP2207806A1 (en) 2010-07-21
HK1151300A1 (en) 2012-01-27
KR20150138405A (ko) 2015-12-09
CA2704024A1 (en) 2009-05-07
WO2009056280A8 (en) 2010-06-10
EP2207806B1 (en) 2013-04-10
WO2009056280A1 (en) 2009-05-07
KR20100102103A (ko) 2010-09-20
AU2008317953B2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
JP7606518B2 (ja) 抗ｃｃｒ８抗体及びその使用
JP6018753B2 (ja) Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
DE60220719T2 (de) Antikörper gegen das muc18-antigen
JP2002503676A (ja) Ｆｃレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断
KR20200037434A (ko) 수정된 항체 영역 및 그의 용도
CA2799608A1 (en) Amino acid sequences which enhance peptide conjugate solubility
WO2005014625A1 (ja) 脳移行活性を有するポリペプチド、およびその利用
CA2704024C (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
US20140199314A1 (en) Methods and compositions for regulating iron homeostasis by modulation of bmp-6
JP2014501723A (ja) 抗原隠蔽剤としての使用のための、ヒトラクトフェリン誘導ペプチド
AU2020202611A1 (en) Binding moieties for biofilm remediation
Kitchener et al. Immunocontraception of Eastern Grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein
HK1151300B (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
KR20230024289A (ko) 혈관 누출을 치료하기 위한 방법 및 조성물
US9493538B2 (en) Snares for pathogenic or infectious agents and uses related thereto
US12492251B2 (en) Human blood-brain barrier targeting antibodies
O’Connor et al. Pharmacokinetics of Systemic Drug Delivery
Stocki et al. Blood-brain barrier transport using a high-affinity, brain-selective VNAR (Variable Domain of New Antigen Receptor) antibody targeting transferrin receptor 1
Koerselman et al. Characterization of single domain antibodies that target IL-1R and ef-fectively block IL-1 signaling as a potential DMOAD
JP2025536316A (ja) ウマｉｌ－５に対する抗体および抗体誘導体
CN121057577A (zh) 经修饰的脂质组合物及其用途
BA et al. C REL
DE102006037581A1 (de) Citrusal-Duftstoffrezeptoren
DE10255132A1 (de) Spezifisches Targeting von pharmazeutischen Zusammensetzungen umfassend ein Trägerprotein mit mindestens einem Aminosäureanalogon

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130717

MKLA Lapsed

Effective date: 20181029